Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

International Journal of Cardiology

Volumn 155, Issue 3, 2012, Pages 378-382

  D'Alto, Michele ^a   Romeo, Emanuele ^a   Argiento, Paola ^a   Sarubbi, Berardo ^a   Santoro, Giuseppe ^a   Grimaldi, Nicola ^a   Correra, Anna ^a   Scognamiglio, Giancarlo ^a   Russo, Maria Giovanna ^a   Calabrò, Raffaele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Association therapy; Congenital heart disease; Pulmonary arterial hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; BOSENTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HEMOGLOBIN; SILDENAFIL; WARFARIN;

ADD ON THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; DETERIORATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EISENMENGER COMPLEX; ENDOCARDIAL CUSHION DEFECT; ERYTHROCYTE COUNT; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL STATUS; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART RATE; HEART SINGLE VENTRICLE; HEART VENTRICLE SEPTUM DEFECT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SEROLOGY; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; THROMBOCYTE COUNT; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EISENMENGER COMPLEX; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; PIPERAZINES; PROSPECTIVE STUDIES; PULMONARY WEDGE PRESSURE; PURINES; SULFONAMIDES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84857790009     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.051     Document Type: Article

References (37)

1. I.L. Hoffmann, and S. Kaplan The incidence of congenital heart disease J Am Coll Cardiol 39 2002 1890 1900 (Pubitemid 34628268)
2. P. Wood The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt Br Med J 2 1958 755 762
3. N. Galiè, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
4. K. Dimopoulos, G. Giannakoulas, S.J. Wort, and M.A. Gatzoulis Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications Curr Opin Cardiol 23 2008 545 554
5. G.P. Diller, K. Dimopoulos, and M.G. Kaya Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart 93 2007 974 976 (Pubitemid 47122051)
6. G.P. Diller, K. Dimopoulos, and C.S. Broberg Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study Eur Heart J 27 2006 1737 1742 (Pubitemid 44025362)
7. M. Beghetti, and N. Galiè Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension J Am Coll Cardiol 53 2009 733 740
8. W.E. Hopkins, and A.D. Waggoner Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome Am J Cardiol 89 2002 34 38 (Pubitemid 34066583)
9. N. Galiè, M. Beghetti, and M.A. Gatzoulis Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 2006 48 54
10. M.A. Gatzoulis, M. Beghetti, and N. Galiè Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study Int J Cardiol 127 2008 27 32 (Pubitemid 351707527)
11. O. Sitbon, M. Beghetti, and J. Petit Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects Eur J Clin Invest 36 2006 25 31 (Pubitemid 44179778)
12. R.L. Benza, B.K. Rayburn, and J.A. Tallaj Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease Chest 129 2006 1009 1015
13. S.C. Apostolopoulou, A. Manginas, D.V. Cokkinos, and S. Rammos Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study Heart 93 2007 350 354 (Pubitemid 46579526)
14. M. D'Alto, C.D. Vizza, and E. Romeo Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart 93 2007 621 625 (Pubitemid 46707118)
15. N. Galiè, H.A. Ghofrani, and A. Torbicki Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157
16. Z.S. Lim, A.P. Salmon, J.J. Vettukattil, and G.R. Veldtman Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects Int J Cardiol 118 2007 178 182 (Pubitemid 46604774)
17. E.M. Chau, K.Y. Fan, and W.H. Chow Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension Int J Cardiol 120 2007 301 305 (Pubitemid 47069563)
18. N. Garg, M.K. Sharma, and N. Sinha Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship Int J Cardiol 120 2007 306 313 (Pubitemid 47069567)
19. T. Humpl, J.T. Reyes, H. Holtby, D. Stephens, and I. Adatia Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study Circulation 111 2005 3274 3280 (Pubitemid 40875000)
20. E.D. Michelakis, W. Tymchak, and M. Noga Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension Circulation 108 2003 2066 2069 (Pubitemid 37337580)
21. M.M. Hoeper, I. Markevych, E. Spiekerkoetter, T. Welte, and J. Niedermeyer Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Eur Respir J 26 2005 858 863 (Pubitemid 41632043)
22. D.B. Badesch, G.E. Raskob, and C.G. Elliott Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Chest 137 2010 376 387
23. M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 24 2004 1007 1010 (Pubitemid 39642293)
24. S.C. Mathai, R.E. Girgis, and M.R. Fisher Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur Respir J 29 2007 469 475 (Pubitemid 46372092)
25. N.R. Porhownik, H. Al-Sharif, and Z. Bshouty Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy Can Respir J 15 2008 427 430
26. K. Iversen, A.S. Jensen, T.V. Jensen, N.G. Vejlstrup, and L. Søndergaard Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial Eur Heart J 31 2010 1124 1131
27. V.V. McLaughlin, D.B. Badesch, and M. Delcroix End points and clinical trial design in pulmonary arterial hypertension J Am Coll Cardiol 54 2009 S97 S107
28. P.L. Enright, and D.L. Sherrill Reference equations for the six-minute walk in healthy adults Am J Respir Crit Care Med 158 5 Pt 1 1998 1384 1387
29. G.H. Guyatt, M.J. Sullivan, and P.J. Thompson The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure Can Med Assoc J 132 1985 919 923
30. W. Grossman Clinical measurement of vascular resistance and assessment of vasodilator drugs W. Grossman, Cardiac catheterization and angiography 1991 Lea and Febiger Philadelphia, PA 143 151
31. M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Eur Respir J 22 2003 330 334 (Pubitemid 36987006)
32. H.A. Ghofrani, F. Rose, and R.T. Schermuly Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension J Am Coll Cardiol 42 2003 158 164 (Pubitemid 36760778)
33. M.M. Hoeper, H. Leuchte, and M. Halank Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Eur Respir J 28 2006 691 694 (Pubitemid 46331988)
34. V.V. McLaughlin, R.J. Oudiz, and A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263 (Pubitemid 44924827)
35. M. Humbert, R.J. Barst, and I.M. Robbins Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359 (Pubitemid 39232254)
36. G. Simonneau, L.J. Rubin, and N. Galiè Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
37. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150